Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo

BACKGROUND: Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a multifunctional chaperone/scaffold protein that is upregulated in various cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junmei, Zhang, Ranran, Su, Tong, Zhou, Qianqian, Gao, Lin, He, Zongyue, Wang, Xin, Zhao, Jian, Xing, Yuanxin, Sun, Feifei, Cai, Wenjie, Wang, Xinpei, Han, Jingying, Qin, Ruixi, Désaubry, Laurent, Han, Bo, Chen, Weiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199526/
https://www.ncbi.nlm.nih.gov/pubmed/37210546
http://dx.doi.org/10.1186/s13046-023-02695-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199526/
https://www.ncbi.nlm.nih.gov/pubmed/37210546
http://dx.doi.org/10.1186/s13046-023-02695-0

Ejemplares similares